Cluster Analysis Identifies Clinical Phenotypes of Primary Hyperhidrosis.

IF 2.8 4区医学 Q2 DERMATOLOGY

Skin Pharmacology and Physiology Pub Date : 2024-08-28 DOI:10.1159/000540516

Mattias A S Henning, Gregor B E Jemec, Ole B Pedersen, Elisabeth H Taudorf

{"title":"Cluster Analysis Identifies Clinical Phenotypes of Primary Hyperhidrosis.","authors":"Mattias A S Henning, Gregor B E Jemec, Ole B Pedersen, Elisabeth H Taudorf","doi":"10.1159/000540516","DOIUrl":null,"url":null,"abstract":"Introduction: Identifying subgroups of patients with primary hyperhidrosis (PHH) can improve the understanding of the disease pathophysiology. The study objective was to determine the naturally occurring subgroups of patients with PHH based on clinical characteristics.Methods: In this retrospective cohort study, data were collected from participants included in a clinical trial. The data were collected between January 2020 and June 2021 from outpatients with PHH attending a dermatologic department in Denmark. Overall, 84 patients with PHH were screened for inclusion in the clinical trial. Of these, 41 met the eligibility criteria. Four participants were excluded because of missing data. The main outcome was the identification of subgroups of patients with PHH using an unsupervised hierarchical cluster analysis.Results: Overall, 37 patients were included {28 (76.7%) females; median age at inclusion 28.0 (interquartile range [IQR] 24.0-38.3); median body mass index 24.9 (IQR 20.9-27.4); median age of onset 13.0 (IQR 9.5-18.5); and 26 (70.3%) had a familial disposition toward PHH}. Two clusters of 18 and 17 patients were identified. The first cluster had, when compared to the second, a younger age of onset (median age 11.0 [IQR 0-13.0] vs. 17.0 [IQR 15.0-21.0], p = 0.003) and higher sweat rates on gravimetry (median 175.0 [IQR 121.2-252.5] vs. 40.0 [IQR 20.0-60.0] milligrams of sweat/5 min, p < 0.001) and transepidermal water loss (median 93.7 [IQR 91.2-97.8] vs. 59.0 [IQR 44.4-73.2] g/m2/h, p < 0.001). No differences were observed for the other variables.Conclusions: This study identifies 2 subgroups of patients with PHH. The patients with an onset of PHH during childhood had a substantially higher sweat and evaporation rate in adulthood than those with an onset during adolescence. These findings may imply a changed understanding of the pathophysiology of PHH, by indicating that an early disease onset can lead to a worse disease course.","PeriodicalId":21748,"journal":{"name":"Skin Pharmacology and Physiology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin Pharmacology and Physiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540516","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Identifying subgroups of patients with primary hyperhidrosis (PHH) can improve the understanding of the disease pathophysiology. The study objective was to determine the naturally occurring subgroups of patients with PHH based on clinical characteristics.

Methods: In this retrospective cohort study, data were collected from participants included in a clinical trial. The data were collected between January 2020 and June 2021 from outpatients with PHH attending a dermatologic department in Denmark. Overall, 84 patients with PHH were screened for inclusion in the clinical trial. Of these, 41 met the eligibility criteria. Four participants were excluded because of missing data. The main outcome was the identification of subgroups of patients with PHH using an unsupervised hierarchical cluster analysis.

Results: Overall, 37 patients were included {28 (76.7%) females; median age at inclusion 28.0 (interquartile range [IQR] 24.0-38.3); median body mass index 24.9 (IQR 20.9-27.4); median age of onset 13.0 (IQR 9.5-18.5); and 26 (70.3%) had a familial disposition toward PHH}. Two clusters of 18 and 17 patients were identified. The first cluster had, when compared to the second, a younger age of onset (median age 11.0 [IQR 0-13.0] vs. 17.0 [IQR 15.0-21.0], p = 0.003) and higher sweat rates on gravimetry (median 175.0 [IQR 121.2-252.5] vs. 40.0 [IQR 20.0-60.0] milligrams of sweat/5 min, p < 0.001) and transepidermal water loss (median 93.7 [IQR 91.2-97.8] vs. 59.0 [IQR 44.4-73.2] g/m2/h, p < 0.001). No differences were observed for the other variables.

Conclusions: This study identifies 2 subgroups of patients with PHH. The patients with an onset of PHH during childhood had a substantially higher sweat and evaporation rate in adulthood than those with an onset during adolescence. These findings may imply a changed understanding of the pathophysiology of PHH, by indicating that an early disease onset can lead to a worse disease course.

查看原文本刊更多论文

聚类分析确定了原发性多汗症的临床表型。

导言：确定原发性多汗症（PHH）患者的亚组可以提高对该疾病病理生理学的认识。本研究旨在根据临床特征确定自然发生的原发性多汗症患者亚组。方法在这项回顾性队列研究中，我们从一项临床试验的参与者中收集了数据。数据收集时间为 2020 年 1 月至 2021 年 6 月，对象是在丹麦皮肤科就诊的 PHH 门诊患者。共筛选出 84 名 PHH 患者参与临床试验。其中 41 人符合资格标准。四名参与者因数据缺失而被排除在外。主要结果是通过无监督分层聚类分析确定 PHH 患者的亚组。结果共纳入 37 名患者（28 名[76.7%]为女性；纳入时年龄中位数为 28.0 [四分位数间距 (IQR) 24.0-38.3]；体重指数中位数为 24.9 [IQR 20.9-27.4]；发病年龄中位数为 13.0 [IQR 9.5-18.5]；26 名[70.3%]具有 PHH 家族遗传倾向）。两个群组分别有 18 名和 17 名患者。与第二个群组相比，第一个群组的发病年龄较小（中位年龄 11.0 [IQR 0-13.0] vs. 17.0 [IQR 15.0-21.0]，P=0.003），体重测量的出汗率较高（中位体重 175.0 [IQR 121.2-252.5]对 40.0 [IQR 20.0-60.0] 毫克汗/5 分钟，p<0.001）和经表皮失水（中位数 93.7 [IQR 91.2-97.8] 对 59.0 [IQR 44.4-73.2] 克/米2/小时，p<0.001）。其他变量无差异。结论本研究确定了 PHH 患者的两个亚组。儿童期发病的 PHH 患者成年后的出汗率和蒸发率大大高于青少年期发病的患者。这些发现可能意味着人们对 PHH 病理生理学的认识发生了变化，表明早期发病会导致病情恶化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Skin Pharmacology and Physiology 医学-皮肤病学

CiteScore

5.20

自引率

7.40%

发文量

审稿时长

>12 weeks

期刊介绍： In the past decade research into skin pharmacology has rapidly developed with new and promising drugs and therapeutic concepts being introduced regularly. Recently, the use of nanoparticles for drug delivery in dermatology and cosmetology has become a topic of intensive research, yielding remarkable and in part surprising results. Another topic of current research is the use of tissue tolerable plasma in wound treatment. Stimulating not only wound healing processes but also the penetration of topically applied substances into the skin, this novel technique is expected to deliver very interesting results.